Standard Biotools Inc (LAB) - Total Assets
Based on the latest financial reports, Standard Biotools Inc (LAB) holds total assets worth $639.11 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore LAB operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Standard Biotools Inc - Total Assets Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's total assets have evolved over time, based on quarterly financial data. See what is Standard Biotools Inc's book value for net asset value and shareholders' equity analysis.
Standard Biotools Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Standard Biotools Inc's total assets of $639.11 Million consist of 80.0% current assets and 20.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $13.43 Million | 2.4% |
| Inventory | $19.98 Million | 3.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Standard Biotools Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Standard Biotools Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Standard Biotools Inc's current assets represent 80.0% of total assets in 2025, a decrease from 85.2% in 2006.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 68.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 3.5% of total assets.
Standard Biotools Inc Competitors by Total Assets
Key competitors of Standard Biotools Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
Standard Biotools Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.36 | 6.12 | 1.48 |
| Quick Ratio | 11.92 | 5.37 | 1.01 |
| Cash Ratio | 0.00 | 2.68 | 0.58 |
| Working Capital | $479.25 Million | $287.78 Million | $25.36 Million |
Standard Biotools Inc - Advanced Valuation Insights
This section examines the relationship between Standard Biotools Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | $567.75 Million |
| Market Capitalization | $339.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Standard Biotools Inc's assets below their book value (0.60x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Standard Biotools Inc's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Standard Biotools Inc (2006–2025)
The table below shows the annual total assets of Standard Biotools Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $567.75 Million | -7.28% |
| 2024-12-31 | $612.34 Million | +89.54% |
| 2023-12-31 | $323.07 Million | -17.23% |
| 2022-12-31 | $390.31 Million | +41.82% |
| 2021-12-31 | $275.21 Million | -15.26% |
| 2020-12-31 | $324.76 Million | +22.64% |
| 2019-12-31 | $264.81 Million | -12.79% |
| 2018-12-31 | $303.65 Million | +5.67% |
| 2017-12-31 | $287.35 Million | -6.22% |
| 2016-12-31 | $306.39 Million | -17.43% |
| 2015-12-31 | $371.06 Million | -8.96% |
| 2014-12-31 | $407.56 Million | +248.59% |
| 2013-12-31 | $116.92 Million | +2.80% |
| 2012-12-31 | $113.73 Million | +43.37% |
| 2011-12-31 | $79.33 Million | +219.85% |
| 2010-12-31 | $24.80 Million | -22.87% |
| 2009-12-31 | $32.15 Million | -0.62% |
| 2008-12-31 | $32.35 Million | -40.93% |
| 2007-12-31 | $54.78 Million | +50.10% |
| 2006-12-31 | $36.49 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consum… Read more